Woods Keith — SEC Form 4 filings
SEC reporting owner CIK 1996804. 15 Form 4 filings on record with FilingPulse; latest filed 2026-06-16.
Transaction summary — filings shown
Covers all 15 filings on record, filed 2024-06-11 to 2026-06-16. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 2 legs across 2 filings — 26,966 shares, $1,221,706 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 14.
- Largest priced transaction: sale of 16,746 shares @ $42.70 ($715,054) in Scholar Rock Holding Corp, filed 2026-01-15.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | Chief Operating Officer | 5 | — | 2 legs · 26,966 sh · $1,221,706 | 4 |
| Neurogene Inc. (NGNE) | Director | 4 | — | — | 4 |
| TScan Therapeutics, Inc. (TCRX) | Director | 3 | — | — | 3 |
| X4 Pharmaceuticals, Inc (XFOR) | Director | 2 | — | — | 2 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | Director | 1 | — | — | 1 |
Form 4 filings — Woods Keith
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-16 | 4/A | Neurogene Inc. (NGNE) | Grant/award (A): 12,050 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4/A | Neurogene Inc. (NGNE) | Grant/award (A): 7,700 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4/A | Neurogene Inc. (NGNE) | Grant/award (A): 15,400 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | TScan Therapeutics, Inc. (TCRX) | Grant/award (A): 67,000 (derivative) @ $0 | EDGAR |
| 2026-04-20 | 4 | Scholar Rock Holding Corp (SRRK) | Sale (S): 10,220 @ $49.57 | EDGAR |
| 2026-02-24 | 4 | Neurogene Inc. (NGNE) | Grant/award (A): 12,050 (derivative) @ $0 | EDGAR |
| 2026-02-11 | 4 | Scholar Rock Holding Corp (SRRK) | Grant/award (A): 47,021 @ $0 | EDGAR |
| 2026-01-15 | 4 | Scholar Rock Holding Corp (SRRK) | Sale (S): 16,746 @ $42.70 | EDGAR |
| 2025-07-02 | 4 | TScan Therapeutics, Inc. (TCRX) | Grant/award (A): 67,000 (derivative) @ $0 | EDGAR |
| 2025-06-10 | 4 | X4 Pharmaceuticals, Inc (XFOR) | Grant/award (A): 1,500 @ $0 | EDGAR |
| 2025-05-06 | 4 | Scholar Rock Holding Corp (SRRK) | Grant/award (A): 110,067 (derivative) @ $0 | EDGAR |
| 2025-04-29 | 4 | Scholar Rock Holding Corp (SRRK) | Grant/award (A): 100,000 @ $0 · Grant/award (A): 500,000 @ $0 | EDGAR |
| 2024-06-20 | 4 | ROCKET PHARMACEUTICALS, INC. (RCKT) | Grant/award (A): 23,944 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | TScan Therapeutics, Inc. (TCRX) | Grant/award (A): 47,500 (derivative) @ $0 | EDGAR |
| 2024-06-11 | 4 | X4 Pharmaceuticals, Inc (XFOR) | Grant/award (A): 45,000 @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1996804 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →